469 related articles for article (PubMed ID: 19013295)
1. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
Gómez-Domínguez E; Gisbert JP; Moreno-Monteagudo JA; García-Buey L; Moreno-Otero R
Aliment Pharmacol Ther; 2006 Jun; 23(11):1643-7. PubMed ID: 16696815
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Georgescu EF; Georgescu M
J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
[TBL] [Abstract][Full Text] [Related]
5. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Kimura Y; Hyogo H; Yamagishi S; Takeuchi M; Ishitobi T; Nabeshima Y; Arihiro K; Chayama K
J Gastroenterol; 2010 Jul; 45(7):750-7. PubMed ID: 20112031
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
8. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.
Musso G; Gambino R; Durazzo M; Biroli G; Carello M; Fagà E; Pacini G; De Michieli F; Rabbione L; Premoli A; Cassader M; Pagano G
Hepatology; 2005 Nov; 42(5):1175-83. PubMed ID: 16231364
[TBL] [Abstract][Full Text] [Related]
9. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
10. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
Kiyici M; Gulten M; Gurel S; Nak SG; Dolar E; Savci G; Adim SB; Yerci O; Memik F
Can J Gastroenterol; 2003 Dec; 17(12):713-8. PubMed ID: 14679419
[TBL] [Abstract][Full Text] [Related]
12. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
[TBL] [Abstract][Full Text] [Related]
13. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Samy W; Hassanian MA
Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
[TBL] [Abstract][Full Text] [Related]
14. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
15. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
[TBL] [Abstract][Full Text] [Related]
16. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
[TBL] [Abstract][Full Text] [Related]
17. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
18. Serum leptin levels in patients with nonalcoholic steatohepatitis.
Uygun A; Kadayifci A; Yesilova Z; Erdil A; Yaman H; Saka M; Deveci MS; Bagci S; Gulsen M; Karaeren N; Dagalp K
Am J Gastroenterol; 2000 Dec; 95(12):3584-9. PubMed ID: 11151896
[TBL] [Abstract][Full Text] [Related]
19. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.
Bahcecioglu IH; Yalniz M; Ataseven H; Ilhan N; Ozercan IH; Seckin D; Sahin K
Hepatogastroenterology; 2005; 52(65):1549-53. PubMed ID: 16201116
[TBL] [Abstract][Full Text] [Related]
20. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]